GPC1 and neoplasm: Moreover, results of the Western blot analysis of tumor samples indicated that the short-term anti-GPC1 mAb treatment had little effect on the activity of the MEK/ERK/RSK and Akt/GSK3/mTOR pathways (Figure 9 and Figure 13).